Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Runcaciguat modified release - Bayer

Next Previous
X
Search
Drug Profile

Runcaciguat modified release - Bayer

Alternative Names: BAY 1101042; sGC Activator 1

Latest Information Update: 08 Jul 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bayer
  • Class Amines; Chlorobenzenes; Cyclopropanes; Fluorinated hydrocarbons; Propionic acids; Small molecules; Urologics
  • Mechanism of Action Guanylate cyclase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Diabetic retinopathy; Renal failure

Most Recent Events

  • 22 Apr 2024 Bayer completes the phase II trial in Diabetic retinopathy in Germany, Poland, Portugal, US, Bulgaria, Latvia, Netherlands, Romania, Slovakia, Spain, Switzerland, UK (PO) (EudraCT2020-002333-15) (NCT04722991)
  • 29 Apr 2022 Bayer completes the CONCORD phase II trial in Renal failure in Germany, Israel, Slovakia, Ukraine, Sweden, Poland, Italy, Finland, Bulgaria, Spain, Belgium, Austria, Denmark (PO) (NCT04507061)
  • 13 Jul 2021 Bayer prematurely terminates its phase I trial in Renal failure (In Volunteers) in Germany (PO, Tablet) due to changes in the company's development strategy(NCT04820621) (EudraCT2020-005716-22)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top